There is evidence that the neutral CB1R-selective antagonist without intrinsic activity (29), AM4113, has been reported to have anti-obesity effects at doses that do not induce symptoms of nausea and vomiting (29,30). The gene discussed is CNR1; the disease is obesity disorder.